As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

A meditation on the effects of putting off doctors' orders.

An increase in screen time has led to a rise in binocular vision disorders.

Look out for at-risk patients and prepare to establish treatment protocols.

In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.

Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

Ruth Shoge, OD, MPH, FAAO, shares key takeaways from her EyeCon 2022 presentation, "Diversity in practice, creating an inclusive and equitable workspace."

Multiple sclerosis is a neurodegenerative disease with ophthalmic manifestations. Although some cases come to attention following an attack of optic neuritis, embedded optic atrophy can be observed in other, longer-standing cases.

When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

Adam Ramsey, OD, shares key takeaways from his EyeCon 2022 presentation, "Advances in industry innovations to improve your practice."

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

Optometry Times' EyeCon co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, MA, OD, FAAO, reflect on the 2023 EyeConversations keynote address, which covered new technology, artificial intelligence, and an update in pharmacology.

Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA , shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.

Panel discusses the highs and lows of treating patients with this condition.